Evofem Biosciences Announces Financial Results for the Second Quarter of 2023

$EVFM
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $EVFM alert in real time by email

— On track to achieve third consecutive year of revenue growth –

— Second consecutive quarter of favorable net product sales to sales and marketing expense ratio —

— Reduced total operating expenses 68% —

— Decreased loss from operations by 70% —

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2023.

EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

"This marks the second consecutive quarter in which our net product sales surpassed our sales and marketing costs. Our small but mighty sales team of 16 sales representatives consistently generates weekly Phexxi prescriptions of 2,000 or more, and I want to commend them for their hard work which continues to deliver tangible results," said Saundra Pelletier, CEO of Evofem Biosciences. "The reported net sales were lower than anticipated due to unexpected returns received in the second quarter of product with short-dated shelf life. We do not anticipate similar returns of short-dated Phexxi to impact future quarters' net revenue, and we remain on track to deliver our third consecutive year of Phexxi net sales growth."

Financial Results

For the three months ended June 30, 2023, net product sales were $2.5 million compared to $6.0 million in the prior year period. The 59% decrease was primarily due to lower Phexxi® (lactic acid, citric acid and potassium bitartrate) ex-factory unit sales due to the absence of marketing and DTC promotion and the 73% reduction in sales force in the current period, coupled with $1.6 million in product returns in the current period; this was product manufactured to meet anticipated demand based on pre-launch, pre-COVID sales forecasting. At the time of manufacture, the product shelf life was 30 months. We succeeded in extending the product shelf life to 48 months in June 2022, but product sold prior to that date could not be relabeled. Because COVID hindered our ability to access HCPs, fully execute on our commercial strategy and meet forecasted sales levels, some of the 30-month labelled product was returned. These factors were offset, in part, by more favorable payer coverage in the current period.

Total operating expenses decreased 68% to $9.8 million, compared to $30.5 million in the prior year period.

  • We decreased selling and marketing costs by 82% to $2.2 million, compared to $12.3 million in the prior year. The decrease largely reflects lower marketing and DTC promotion costs, lower media agency fees, and a 73% reduction in sales force and 100% reduction in marketing headcount in the current period compared to the second quarter of 2022.
  • Our research and development costs decreased 95% to $0.4 million, compared to $7.7 million in the prior year period.
  • Our general and administrative costs decreased 46% to $4.9 million, compared to $9.1 million in the prior year period.
  • Cost of goods sold increased 78% to $2.3 million, compared to $1.3 million in the prior year period, primarily due to a $1.1 million inventory excess and obsolete reserve recorded in the current period. Additionally, several lots were re-packaged in order to comply with the extended shelf life approved by the FDA in June 2022; this re-package work increased cost of goods sold in the second quarter of 2023 but will lead to less excess and obsolete inventory going forward.

As a result, net loss attributable to common stockholders improved to $8.6 million, or $(5.43) per share, for the three months ended June 30, 2023, compared with a net loss attributable to common shareholders of $124.1 million, or $(580.48) per share, for the three months ended June 30, 2022.

Liquidity

In April 2023, we raised $0.5 million in net proceeds through the sale and issuance of senior secured convertible notes and warrants to certain investors.

At June 30, 2023, we had $0.6 million of restricted and unrestricted cash, as compared to $4.8 million of restricted and unrestricted cash at December 31, 2022.

Subsequent Material Events

  • Raised $1.0 million in net proceeds through the sale and issuance of senior secured convertible notes and warrants to certain investors in July 2023.
  • In July 2023, our board of directors adopted and approved an amendment and restatement of our Amended and Restated Bylaws. Among the changes, i) Board Consent is no longer required to reschedule the Company's annual meeting and ii) the proportion of shares present required to constitute a quorum at a meeting of stockholders changed from a majority to one-third of the outstanding shares of stock entitled to vote, as permitted under § 216 of the Delaware General Corporation Law.
  • Raised $0.5 million in net proceeds, after deducting legal fees and offering costs, through the sale and issuance of senior secured convertible notes and warrants to certain investors in August 2023.
  • In August 2023, the Company filed a Certificate of Designation of Series E-1 Convertible Preferred Stock, par value $0.0001 per share. An aggregate of 2,300 shares was authorized, are convertible into shares of Common Stock at a conversion price of $0.40 per share and are both counted toward quorum based on, and have voting rights equal to, the number of shares of Common Stock into which the Series E-1 Convertible Preferred Shares are then convertible. The Series E-1 Convertible Preferred Shares are entitled to dividends, payable in shares of Common Stock. As filed with the SEC on form 8-K on August 10, 2023, certain investors party to the December 2022 Notes and the February 2023 Notes exchanged $1.8 million total notes for 1,800 shares of Series E-1 Preferred Stock.

About Evofem Biosciences

Evofem Biosciences, Inc., is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com. 

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the Company's anticipated financial performance. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 27, 2023 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contact

Amy Raskopf

Evofem Biosciences, Inc.

araskopf@evofem.com

(917) 673-5775

-- Financial Tables Follow --

EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS



(Unaudited)

(In thousands, except par value and share data)













As of







June 30, 2023





December 31, 2022



Assets

















Current assets:

















Cash and cash equivalents



$

-





$

2,769



Restricted cash





636







1,207



Trade accounts receivable, net





5,198







1,126



Total current liabilities





69,716







93,830



Total stockholders' deficit





(55,664)







(71,800)



Total liabilities, convertible and redeemable preferred stock and stockholders' deficit



$

14,074





$

25,163



 

EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS



(Unaudited)

(In thousands, except share and per share data)



















Three Months Ended June 30,





Six Months Ended June 30,







2023





2022





2023





2022





























Product sales, net



$

2,458







6,034





$

8,267





$

10,285





































Operating Expenses:

































Cost of goods sold





2,293







1,285







3,669







2,351



Research and development





402







7,744







942







18,135



Selling and marketing





2,197







12,298







6,051







25,003



General and administrative





4,902







9,126







8,520







18,144



Total operating expenses





9,794







30,453







19,182







63,633



Loss from operations





(7,336)







(24,419)







(10,915)







(53,348)



Other income (expense):

































Interest income





8







4







26







5



Other expense, net





(1,127)







(415)







(1,445)







(886)



Loss on issuance of financial instruments





(27)







(71,150)







(111)







(72,002)



Change in fair value of financial instruments





(73)







(29,980)







1,539







(31,614)



Total other income (expense), net





(1,219)







(101,541)







9







(104,497)



Loss before income tax





(8,555)







(125,960)







(10,906)







(157,845)



Income tax expense





(3)







(20)







(6)







(23)



Net loss





(8,558)







(125,980)







(10,912)







(157,868)



Convertible preferred stock deemed dividends





-







1,908







-







1,827



Net loss attributable to common stockholders



$

(8,558)





$

(124,072)





$

(10,912)





$

(156,041)



Net loss per share, basic and diluted



$

(5.43)





$

(580.48)





$

(6.60)





$

(169.73)



Weighted-average shares used to compute net loss, basic and diluted





1,576,158







217,028







1,654,026







930,112



 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-financial-results-for-the-second-quarter-of-2023-301900203.html

SOURCE Evofem Biosciences, Inc.

Get the next $EVFM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EVFM

DatePrice TargetRatingAnalyst
3/4/2022$0.50 → $0.53Underweight
Morgan Stanley
11/16/2021$2.50 → $2.00Buy
HC Wainwright & Co.
10/21/2021$4.00 → $2.50Buy
HC Wainwright & Co.
10/14/2021$0.80Equal-Weight → Underweight
Morgan Stanley
8/12/2021$3.00 → $1.00Equal-Weight
Morgan Stanley
More analyst ratings

$EVFM
Press Releases

Fastest customizable press release news feed in the world

See more
  • Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

    Event exploring the increasing risk of emerging infectious diseases Update on Appili transaction and recent operational highlights, including $117M submitted in federal funding applications Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics Inc. ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, will be joining at the upcoming Aditxt Weekly Update. The event, scheduled on April 4 at 11:30 am ET, will highlight the urgent need for infectious disease treatm

    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

    The event will begin today at 11:30 a.m. ET Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University Aditxt, Inc. (NASDAQ:ADTX), ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that today's Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. ("Pearsanta"). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and othe

    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

    -- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO, March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse. It prevents pregnancy by maintaining the normal vaginal biome which has a slightly acidic pH that is inhospitable to sperm.

    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$EVFM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EVFM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EVFM
SEC Filings

See more

$EVFM
Leadership Updates

Live Leadership Updates

See more
  • Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

    SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Bioscien

    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EVFM
Financials

Live finance-specific insights

See more
  • Evofem Reports Fourth Consecutive Year of Net Sales Growth

    -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

    $ADTX
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

    — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

    — Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EVFM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more